Skip to main content
SpringerLink
Log in

Peritoneal Metastasis of Retroperitoneal Tumors

  • Chapter
  • First Online:
Unusual Cases in Peritoneal Surface Malignancies

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rajiah P, Sinha R, Cuevas C, Dubinsky TJ, Bush Jr WH, Kolokythas O. Imaging of uncommon retroperitoneal masses. Radiographics. 2011;31(4):949–76. doi:10.1148/rg.314095132.

    Article  PubMed  Google Scholar 

  2. Neville A, Herts BR. CT characteristics of primary retroperitoneal neoplasms. Crit Rev Comput Tomogr. 2004;45(4):247–70.

    Article  PubMed  Google Scholar 

  3. Karakousis CP, Blumenson LE, Canavese G, Rao U. Surgery for disseminated abdominal sarcoma. Am J Surg. 1992;163(6):560–4.

    Article  CAS  PubMed  Google Scholar 

  4. Bilimoria MM, Holtz DJ, Mirza NQ, Feig BW, Pisters PW, Patel S, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer. 2002;94(9):2441–6. doi:10.1002/cncr.10504.

    Article  PubMed  Google Scholar 

  5. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–7.

    Article  CAS  PubMed  Google Scholar 

  6. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 2000;88(1):66–74.

    Article  CAS  PubMed  Google Scholar 

  7. Munene G, Mack LA, Temple WJ. Systematic review on the efficacy of multimodal treatment of sarcomatosis with cytoreduction and intraperitoneal chemotherapy. Ann Surg Oncol. 2011;18(1):207–13. doi:10.1245/s10434-010-1229-3.

    Article  PubMed  Google Scholar 

  8. O’Sullivan PJ, Harris AC, Munk PL. Radiological imaging features of non-uterine leiomyosarcoma. Br J Radiol. 2008;81(961):73–81. doi:10.1259/bjr/18595145.

    Article  PubMed  Google Scholar 

  9. Hartman DS, Hayes WS, Choyke PL, Tibbetts GP. From the archives of the AFIP. Leiomyosarcoma of the retroperitoneum and inferior vena cava: radiologic-pathologic correlation. Radiographics. 1992;12(6):1203–20. doi:10.1148/radiographics.12.6.1439022.

    Article  CAS  PubMed  Google Scholar 

  10. McLeod AJ, Zornoza J, Shirkhoda A. Leiomyosarcoma: computed tomographic findings. Radiology. 1984;152(1):133–6. doi:10.1148/radiology.152.1.6729102.

    Article  CAS  PubMed  Google Scholar 

  11. Courtney MW, Levine EA. Uterine leiomyosarcoma metastatic to soft tissue of the flank following a ten-year disease-free interval. South Med J. 2009;102(3):325–6. doi:10.1097/SMJ.0b013e318195132a.

    Article  PubMed  Google Scholar 

  12. Burke JP, Maguire D, Dillon J, Moriarty M, O’Toole GC. Whipple’s procedure for an oligometastasis to the pancreas from a leiomyosarcoma of the thigh. Ir J Med Sci. 2012;181(3):361–3. doi:10.1007/s11845-009-0447-9.

    Article  CAS  PubMed  Google Scholar 

  13. Gibbs JF, Huang PP, Lee RJ, McGrath B, Brooks J, McKinley B, et al. Malignant fibrous histiocytoma: an institutional review. Cancer Investig. 2001;19(1):23–7.

    Article  CAS  Google Scholar 

  14. Putnam Jr JB, Roth JA. Surgical treatment for pulmonary metastases from sarcoma. Hematol Oncol Clin North Am. 1995;9(4):869–87.

    PubMed  Google Scholar 

  15. Yoo JW, Lee DH, Song HJ, Ahn JH, Kim SW, Suh C, et al. Peritoneal dissemination from malignant fibrous histiocytoma of the buttock: unusual metastases from a rare tumor. Gut Liver. 2008;2(3):213–5. doi:10.5009/gnl.2008.2.3.213.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Stavropoulos NJ, Deliveliotis C, Kouroupakis D, Demonakou M, Kastriotis J, Dimopoulos C. Renal cell carcinoma presenting as a large abdominal mass with an extensive peritoneal metastasis. Urol Int. 1995;54(3):169–70.

    Article  CAS  PubMed  Google Scholar 

  17. Tartar VM, Heiken JP, McClennan BL. Renal cell carcinoma presenting with diffuse peritoneal metastases: CT findings. J Comput Assist Tomogr. 1991;15(3):450–3.

    Article  CAS  PubMed  Google Scholar 

  18. Staderini F, Cianchi F, Badii B, Skalamera I, Fiorenza G, Foppa C, et al. A unique presentation of a renal clear cell carcinoma with atypical metastases. Int J Surg Case Rep. 2015;11:29–32. doi:10.1016/j.ijscr.2015.03.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Acar O, Mut T, Saglican Y, Sag AA, Falay O, Selcukbiricik F, et al. Isolated omental metastasis of renal cell carcinoma after extraperitoneal open partial nephrectomy: a case report. Int J Surg Case Rep. 2016;21:6–11. doi:10.1016/j.ijscr.2016.02.008.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872–8. doi:10.1007/s00268-005-0329-x.

    Article  PubMed  Google Scholar 

  21. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94(6):1853–78. doi:10.1210/jc.2008-2291.

    Article  CAS  PubMed  Google Scholar 

  22. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551–64. doi:10.1210/jc.2013-3020.

    Article  CAS  PubMed  Google Scholar 

  23. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579–86. doi:10.1016/j.ejca.2013.02.034.

    Article  PubMed  Google Scholar 

  24. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115(2):243–50. doi:10.1002/cncr.24030.

    Article  PubMed  Google Scholar 

  25. Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169(3):263–70. doi:10.1530/EJE-13-0242.

    Article  CAS  PubMed  Google Scholar 

  26. Gratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S, et al. Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Ann Surg Oncol. 2014;21(11):3509–14. doi:10.1245/s10434-014-3931-z.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DH, Dudas ME, et al. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol. 2003;16(8):742–51. doi:10.1097/01.MP.0000081730.72305.81.

    Article  PubMed  Google Scholar 

  28. Kerkhofs TM, Verhoeven RH, Bonjer HJ, van Dijkum EJ, Vriens MR, De Vries J, et al. Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013;169(1):83–9. doi:10.1530/EJE-13-0142.

    Article  CAS  PubMed  Google Scholar 

  29. Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):181–91. doi:10.1210/jc.2012-2559.

    Article  CAS  PubMed  Google Scholar 

  30. Dy BM, Wise KB, Richards ML, Young Jr WF, Grant CS, Bible KC, et al. Operative intervention for recurrent adrenocortical cancer. Surgery. 2013;154(6):1292–9. discussion 9 doi:10.1016/j.surg.2013.06.033.

    Article  PubMed  Google Scholar 

  31. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189–97. doi:10.1056/NEJMoa1200966.

    Article  CAS  PubMed  Google Scholar 

  32. Carrion A, Huguet J, Garcia-Cruz E, Izquierdo L, Mateu L, Musquera M, et al. Intraoperative prognostic factors and atypical patterns of recurrence in patients with upper urinary tract urothelial carcinoma treated with laparoscopic radical nephroureterectomy. Scand J Urol. 2016:1–8. doi:10.3109/21681805.2016.1144219.

  33. Hollenbeck ST, Grobmyer SR, Kent KC, Brennan MF. Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. J Am Coll Surg. 2003;197(4):575–9. doi:10.1016/S1072-7515(03)00433-2.

    Article  PubMed  Google Scholar 

  34. Wachtel H, Gupta M, Bartlett EK, Jackson BM, Kelz RR, Karakousis GC, et al. Outcomes after resection of leiomyosarcomas of the inferior vena cava: a pooled data analysis of 377 cases. Surg Oncol. 2015;24(1):21–7. doi:10.1016/j.suronc.2014.10.007.

    Article  PubMed  Google Scholar 

  35. Mingoli A, Cavallaro A, Sapienza P, Di Marzo L, Feldhaus RJ, Cavallari N. International registry of inferior vena cava leiomyosarcoma: analysis of a world series on 218 patients. Anticancer Res. 1996;16(5B):3201–5.

    CAS  PubMed  Google Scholar 

  36. Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, et al. Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol. 2007;14(12):3534–41. doi:10.1245/s10434-007-9552-z.

    Article  PubMed  Google Scholar 

  37. Kieffer E, Alaoui M, Piette JC, Cacoub P, Chiche L. Leiomyosarcoma of the inferior vena cava: experience in 22 cases. Ann Surg. 2006;244(2):289–95. doi:10.1097/01.sla.0000229964.71743.db.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Wachtel H, Jackson BM, Bartlett EK, Karakousis GC, Roses RE, Bavaria JE, et al. Resection of primary leiomyosarcoma of the inferior vena cava (IVC) with reconstruction: a case series and review of the literature. J Surg Oncol. 2015;111(3):328–33. doi:10.1002/jso.23798.

    Article  PubMed  Google Scholar 

  39. Illum.....inati G, Calio FG, D’Urso A, Giacobbi D, Papaspyropoulos V, Ceccanei G. Prosthetic replacement of the infrahepatic inferior vena cava for leiomyosarcoma. Arch Surg. 2006;141(9):919–24. discussion 24 doi:10.1001/archsurg.141.9.919.

    Article  Google Scholar 

  40. Daylami R, Amiri A, Goldsmith B, Troppmann C, Schneider PD, Khatri VP. Inferior vena cava leiomyosarcoma: is reconstruction necessary after resection? J Am Coll Surg. 2010;210(2):185–90. doi:10.1016/j.jamcollsurg.2009.10.010.

    Article  PubMed  Google Scholar 

  41. Mann GN, Mann LV, Levine EA, Shen P. Primary leiomyosarcoma of the inferior vena cava: a 2-institution analysis of outcomes. Surgery. 2012;151(2):261–7. doi:10.1016/j.surg.2010.10.011.

    Article  PubMed  Google Scholar 

  42. Cho SW, Marsh JW, Geller DA, Holtzman M, Zeh 3rd H, Bartlett DL, et al. Surgical management of leiomyosarcoma of the inferior vena cava. J Gastrointest Surg. 2008;12(12):2141–8. doi:10.1007/s11605-008-0700-y.

    Article  CAS  PubMed  Google Scholar 

  43. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1993;31(Suppl 2):S174–9.

    PubMed  Google Scholar 

  44. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13(7):1600–8.

    Article  CAS  PubMed  Google Scholar 

  45. Kim JT, Kwon T, Cho Y, Shin S, Lee S, Moon D. Multidisciplinary treatment and long-term outcomes in six patients with leiomyosarcoma of the inferior vena cava. J Korean Surg Soc. 2012;82(2):101–9. doi:10.4174/jkss.2012.82.2.101.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Gronchi A, Miceli R, Allard MA, Callegaro D, Le Pechoux C, Fiore M, et al. Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection. Ann Surg Oncol. 2015;22(5):1447–54. doi:10.1245/s10434-014-4130-7.

    Article  PubMed  Google Scholar 

  47. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717–25. doi:10.1002/ijc.25596.

    Article  CAS  PubMed  Google Scholar 

  48. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699–705. doi:10.1002/bjs.8679.

    Article  CAS  PubMed  Google Scholar 

  49. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608–18. doi:10.1002/cncr.25356.

    Article  PubMed  Google Scholar 

  50. Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20(13):4224–30. doi:10.1245/s10434-013-3145-9.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Esquivel J, Piso P, Verwaal V, Bachleitner-Hofmann T, Glehen O, Gonzalez-Moreno S, et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol. 2014;110(7):777–8. doi:10.1002/jso.23722.

    Article  PubMed  Google Scholar 

  52. Meesters B, Pauwels PA, Pijnenburg AM, Vlasveld LT, Repelaer van Driel OJ. Metastasis in a benign duodenal stromal tumour. Eur J Surg Oncol. 1998;24(4):334–5.

    Article  CAS  PubMed  Google Scholar 

  53. Chung JC, Chu CW, Cho GS, Shin EJ, Lim CW, Kim HC, et al. Management and outcome of gastrointestinal stromal tumors of the duodenum. J Gastrointest Surg. 2010;14(5):880–3. doi:10.1007/s11605-010-1170-6.

    Article  PubMed  Google Scholar 

  54. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist. 2010;15(3):300–7. doi:10.1634/theoncologist.2009-0120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol. 2003;27(5):625–41.

    Article  PubMed  Google Scholar 

  56. Gervaz P, Huber O, Morel P. Surgical management of gastrointestinal stromal tumours. Br J Surg. 2009;96(6):567–78. doi:10.1002/bjs.6601.

    Article  CAS  PubMed  Google Scholar 

  57. Bucher P, Egger JF, Gervaz P, Ris F, Weintraub D, Villiger P, et al. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol. 2006;32(3):310–4. doi:10.1016/j.ejso.2005.11.021.

    Article  CAS  PubMed  Google Scholar 

  58. Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T, et al. Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg. 2005;9(9):1346–53. doi:10.1016/j.gassur.2005.06.016.

    Article  PubMed  Google Scholar 

  59. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63.

    Article  CAS  PubMed  Google Scholar 

  60. Isayama H, Sasaki T, Nakai Y, Togawa O, Kogure H, Sasahira N, et al. Management of malignant gastric outlet obstruction with a modified triple-layer covered metal stent. Gastrointest Endosc. 2012;75(4):757–63. doi:10.1016/j.gie.2011.11.035.

    Article  PubMed  Google Scholar 

  61. Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, et al. Predictive factors of solid food intake in patients with malignant gastric outlet obstruction receiving self-expandable metallic stents for palliation. Dig Endosc. 2012;24(4):226–30. doi:10.1111/j.1443-1661.2011.01208.x.

    Article  PubMed  Google Scholar 

  62. Sasaki T, Isayama H, Maetani I, Nakai Y, Kogure H, Kawakubo K, et al. Japanese multicenter estimation of WallFlex duodenal stent for unresectable malignant gastric outlet obstruction. Dig Endosc. 2013;25(1):1–6. doi:10.1111/j.1443-1661.2012.01319.x.

    Article  PubMed  Google Scholar 

  63. Nakai Y, Ishigami H, Isayama H, Sasaki T, Kawakubo K, Kogure H, et al. Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis. J Gastroenterol Hepatol. 2012;27(12):1796–800. doi:10.1111/j.1440-1746.2012.07241.x.

    Article  CAS  PubMed  Google Scholar 

  64. Thomassen I, Lemmens VE, Nienhuijs SW, Luyer MD, Klaver YL, de Hingh IH. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas. 2013;42(1):72–5. doi:10.1097/MPA.0b013e31825abf8c.

    Article  PubMed  Google Scholar 

  65. Blastik M, Plavecz E, Zalatnai A. Pancreatic carcinomas in a 60-year, institute-based autopsy material with special emphasis of metastatic pattern. Pancreas. 2011;40(3):478–80. doi:10.1097/MPA.0b013e318205e332.

    Article  PubMed  Google Scholar 

  66. Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, et al. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. J Gastrointest Cancer. 2014;45(3):307–11. doi:10.1007/s12029-014-9603-1.

    Article  CAS  PubMed  Google Scholar 

  67. Schneitler S, Kropil P, Riemer J, Antoch G, Knoefel WT, Haussinger D, et al. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World J Gastroenterol. 2015;21(20):6384–90. doi:10.3748/wjg.v21.i20.6384.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. doi:10.1056/NEJMoa1011923.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General, Visceral and Transplantation Surgery and Department of General, Visceral, Vascular and Thoracic Surgery, Campus Virchow and Mitte, Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany

    Andreas Brandl, Christina Barbara Schäfer & Beate Rau MD, PhD

Authors
  1. Andreas Brandl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Barbara Schäfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beate Rau MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beate Rau MD, PhD .

Editor information

Editors and Affiliations

  1. Peritoneal Dissemination Treatment, Istanbul, Turkey

    Emel Canbay

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Brandl, A., Schäfer, C.B., Rau, B. (2017). Peritoneal Metastasis of Retroperitoneal Tumors. In: Canbay, E. (eds) Unusual Cases in Peritoneal Surface Malignancies . Springer, Cham. https://doi.org/10.1007/978-3-319-51523-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-51523-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-51522-9

  • Online ISBN: 978-3-319-51523-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation